Genetics of arterial hypertension and hypotension
- First Online:
- Cite this article as:
- Rosskopf, D., Schürks, M., Rimmbach, C. et al. Naunyn-Schmied Arch Pharmacol (2007) 374: 429. doi:10.1007/s00210-007-0133-2
- 1.1k Downloads
Human hypertension affects affects more than 20% of the adult population in industrialized countries, and it is implicated in millions of deaths worldwide each year from stroke, heart failure and ischemic heart disease. Available evidence suggests a major genetic impact on blood pressure regulation. Studies in monogenic hypertension revealed that renal salt and volume regulation systems are predominantly involved in the genesis of these disorders. Mutations here affect the synthesis of mineralocorticoids, the function of the mineralocorticoid receptor, epithelial sodium channels and their regulation by a new class of kinases, termed WNK kinases. It has been learned from monogenic hypotension that almost all ion transporters involved in the renal uptake of Na+ have a major impact on blood pressure regulation. For essential hypertension as a complex disease, many candidate genes have been analysed. These include components of the renin–angiotensin-aldosterone system, adducin, β-adrenoceptors, G protein subunits, regulators of G protein signalling (RGS) proteins, Rho kinases and G protein receptor kinases. At present, the individual impact of common polymorphisms in these genes on the observed blood pressure variation, on risk for stroke and as predictors of antihypertensive responses remains small and clinically irrelevant. Nevertheless, these studies have greatly augmented our knowledge on the regulation of renal functions, cellular signal transduction and the integration of both. Together, this provides the basis for the identification of novel drug targets and, hopefully, innovative antihypertensive drugs.
KeywordsHypertensionGeneticsPharmacogeneticsStrokeSalt and volume homoiostasisSignal transduction
List of abbreviations
angiotensin converting enzyme
protein kinase AKT
apparent mineralocorticoid excess
- Ang II
angiotensin II receptor, type 1
- CLCNKA, CLCNKB
renal epithelial chloride channels
epithelial sodium channel
endothelial NO synthase
GTPase activating protein
gene of the G protein Gαs subunit
gene of the G protein Gβ3 subunit
G protein-coupled receptor
G protein-coupled receptor kinase
11β-hydroxysteroid dehydrogenase type 2
- MHS, MNS
Milan hypertensive/normotensive strain of rats
thiazide-sensitive Na+/Cl− transporter
- PKA, PKC, PKG
protein kinases A, C, G
quantitative trait locus
regulators of G protein signalling
renal outer medulla K+ channel
- SCNN1A,SCNN1B, SCNN1G
genes for the epithelial sodium channel subunits α, β, γ
sodium and glucocorticoid-induced kinase
single nucleotide polymorphism
protein kinase with no lysine
Before reviewing the genetics of hypertension we have to start with some facts on ‘hypertension’ itself. According to our current understanding, blood pressure is a highly regulated quantity, affected by a multitude of physiological systems that finally integrate and maintain blood pressure levels to secure an adequate blood perfusion of all tissues despite widely varying metabolic demands. Blood pressure values are distributed continuously in a unimodal fashion skewed to the ends of the distribution curves. Given this continuous distribution of blood pressure levels, the classification of ‘hypertension’ as a discrete entity requires the operational definition of blood pressure thresholds above which cardiovascular risk increases or therapeutic interventions are of clinical benefit. Within the last 2 decades, classification thresholds have gradually been reduced owing to improved therapeutic options and refined epidemiologic analyses. Accordingly, ‘hypertension’ prevalences may ultimately comprise a considerable part and eventually the majority of the adult population in industrialized and aging societies in the near future, for instance in Western Europe. Living long enough (and perhaps, becoming fat enough), many of us will develop hypertension, a situation similar to diseases like Alzheimer’s. Hence, we have to understand the pathogenesis of hypertension as a dynamic process potentially beginning in early childhood. On the other hand, some octogenarians or even centenarians still have normal or low blood pressure values. This lends interest to ‘hypotensive’ mechanisms (potentially genes) in addition to the delineation of their hypertensive counterparts.
Second, available evidence suggests that genetic mechanisms contribute to blood pressure regulation. There is a substantial correlation between blood pressure values of parents and children, documenting that the similarity of blood pressure values within families is greater than between families (Longini et al. 1984). Observational studies with monozygotic twins demonstrate greater concordance than with dizygotic twins (Feinleib et al. 1977). Adoption studies further indicate that familial aggregation of blood pressure levels is not simply attributable to shared environment, since biological siblings exhibit a higher concordance than adoptive siblings (Biron et al. 1976; Rice et al. 1989). An analogous situation is the observed variation in body height which is governed by hereditary (including gender as a hereditary factor) and environmental factors (differing between ethnicities). Likewise, environmental and nutritional factors, as well as different lifestyles, contribute to the pathogenesis of primary hypertension as important modifiable risk factors. Guesses (more or less educated) suggest that 30–60% of the observed variation in blood pressure is attributable to genetic factors with five or ten or more (....and even more, if we refer to negative results from recent genome-wide screens in affected families) different genes, each with only a limited impact. Environment (nurture) contributes to the remaining half in blood pressure variation. Together, we face a complex interplay of different blood pressure raising and lowering genes, many with pleiotropic effects, in concert with numerous exogenous factors. In addition, primary hypertension is tightly entangled with the complexities of other disorders including the metabolic syndrome, diabetes type II, preeclampsia or the progress of renal diseases.
Here, we will review the current knowledge on the genetics of hypertension. An innocent search in the Medline database for ‘hypertension and genetics’ will result in a tsunami of many thousands of references, addressing putative connections between the genesis of hypertension and apparently all bodily functions and biological systems. For reasons of space and the scope of a pharmacological journal, we will focus here primarily on hypertension candidate genes that have been characterised in terms of a potential function. Thus, we will skip most of the evidence from pure association or linkage studies, pertaining to anonymous loci. Furthermore, we will concentrate on genetic studies that were confirmed in independent human samples, and animal models of genetic hypertension are only presented if their results show close parallels to the situation in humans.
Citing the sometimes poetic ‘wisdom’ of a former US Secretary of Defence on strategy, there are ‘known knowns’, ‘unknown knowns’, ‘known unknowns’ and ‘unknown unknowns’. At present, genetics of hypertension belong to the ‘known unknowns’ and with ongoing scientific progress we will most likely face many surprising ‘unknown unknowns’. This review, however, addresses ‘known knowns’ which may belong to the ‘unknown knowns’ for some readers. Mendelian forms of hypertension are the most important ‘known knowns’ in the field of hypertension genetics, since they are paradigmatic examples for the pathophysiology of systems primarily involved in blood pressure control. Most rewarding, we can trace the pathomechanisms here from variations in genomic DNA to the phenotype ‘increased blood pressure’.
Monogenic or Mendelian forms of hypertension
Monogenic or Mendelian forms of hypertension are extremely rare disorders. The best described forms are autosomal diseases that are accompanied by a distinct phenotype in addition to elevated blood pressure. Insightful clinical observations allowed for generating pedigrees, performing classical linkage analyses, identifying disease loci and, ultimately, the unravelling of genetic ‘defects’, which are believed to be indicative for similar abnormalities in primary hypertension.
We have included in this review monogenic forms of hypertension syndroms for which hypertension is the leading symptom. Of course, there exist other complex genetic syndromes that are accompanied by a rise in blood pressure, e.g. familial pheochromocytoma, which are out of the scope of this survey. Interestingly, most mutations identified so far directly affect renal Na+ homoeostasis. Increased renal salt absorption is accompanied by increased water reabsorption, resulting in an augmented intravascular volume. In turn, the preload—i.e., the venous blood return to the heart—increases, raising cardiac output and blood pressure. If this situation continues, regulatory processes are activated that also contribute to the maintenance of hypertension.
Glucocorticoid-remediable aldosteronism (GRA)
Now under control of the 11β hydroxylase promoter aldosterone synthase, activity of the chimeric gene is ectopically expressed in the fasciculata of the adrenal gland, where it mediates together with CYP17 (17-α hydroxylase) the synthesis of abnormal 18-hydroxy- and 18-oxycortisol from glucocorticoid precursors. In contrast to the wildtype gene, expression of the chimeric aldosterone synthase gene is no longer regulated by angiotensin II but becomes sensitive to ACTH, which links mineralocorticoid secretion inappropriately to glucocorticoid secretion (Fig. 2b). 18-oxo- and 18-hydroxycortisol bind to the mineralocorticoid receptor (MR) in the distal tubule and cortical collecting duct, and stimulate Na+ absorption coupled to H+ and K+ secretion. Ultimately, this causes plasma volume expansion and a decrease in plasma renin activity with normal or low aldosterone levels. Suppression of ACTH by exogenous glucocorticoids attenuates abnormal steroidogenesis and ameliorates hypertension (Lifton et al. 1992a,b). Women with GRA exhibit an increased risk for preeclampsia (Wyckoff et al. 2000). Following the initial characterization of the molecular mechanisms in GRA, similar unequal crossing over mutations have been identified in other families. In all cases, the breakpoints are located 5′ of intron 4. There is considerable genetic heterogeneity in carriers of the GRA hybrid gene, ranging from normotension, via mild (indistinguishable from primary hypertension) to severe hypertension. This heterogeneity may be attributable in part to different breakpoints, but other genetic and environmental factors appear to play a major role.
Apparent mineralocortiocid excess (AME)
Apparent mineralocorticoid excess was described as a rare autosomal recessive syndrome that comprises severe childhood hypertension, strokes, volume expansion, hypokalemia, and metabolic alkalosis, all symptoms responsive to aldosterone antagonists, despite the virtual absence of aldosterone in blood plasma (New et al. 1977). Based on the obvious similarities with the phenotype of ‘licorice intoxication’ (phenocopy), Mune and co-workers followed a candidate gene approach, and identified homozygous loss-of-function mutations (Arg208Cys; Arg213Cys) in the renal isoform of HSD11B2 in eight of nine families with AME (Mune et al. 1995). Similarly to blocking with glycyrrhetinic acid, the mutated HSD11B2 fails to inactivate cortisol, leaving the MR unprotected. Subsequently, other inactivating mutations in HSD11B2 were identified in different pedigrees (Arg208His; Asp223Asn; Arg279Cys; Arg337Cys; Arg337His; Tyr299del) which explain in part the observed genetic heterogeneity (OMIM, Online-Medelian Inheritance in Man; http://www.ncbi.nlm.nih.gov; accessed November 2006). There is evidence that heterozygous carriers of such mutations may develop late-onset AME (Li et al. 1997). Since AME is accompanied with low renin activity, and 40% of patients with primary hypertension demonstrate low renin levels, speculation was raised that mutations in the HSD11B2 gene on chromosome 16q with moderately decreased enzymatic activity could contribute to the pathogenesis of (salt-sensitive) hypertension and preeclampsia. In two different (inbred) families, HSD11B2 mutations were identified that cause mild low renin hypertension (Wilson et al. 1998; Pro227Leu; Leu114del-Glu115del); however, a relevance of HSD11B2 mutations for primary hypertension remains to be established.
Additional inborn errors in glucocorticoid metabolism, including deficiencies in 11β-hydroxylase or 17α-hydroxylase, result in an inappropriate accumulation of deoxycorticosterone and corticosterone, which are potent mineralocorticoids and cause hypertension similar to AME, but are out of the scope of this review (Kagimoto et al. 1988; White et al. 1991).
Mineralocorticoid receptor mutations and hypertension exacerbated in pregnancy
Liddle’s syndrome describes a rare autosomal dominant disorder that comprises early-onset hypertension, frequently accompanied by metabolic alkalosis and hypokalemia, suppressed plasma renin and aldosterone levels (Liddle et al. 1963). In contrast to AME and GRA, Liddle’s syndrome does not respond to treatment with aldosterone antagonists, but is responsive to thiazides, amiloride and triamterene. A case-report demonstrating that a patient with Liddle’s syndrome and renal insufficiency was cured upon renal transplantation indicated that the cause for this disease resides in the kidneys (Botero-Velez et al. 1994). Subsequent linkage analysis based on pedigrees with Liddle’s syndrome detected a locus on chromosome 16 near the position of the β subunit (gene: SCNN1B) of the epithelial Na+ channel (ENaC; Shimkets et al. 1994; Hannson et al. 1995a; Inoue et al. 1998) followed by similar observations in the ENaC γ subunit gene, also on chromosome 16 (gene: SCNN1G; Hannson et al. 1995b), indicating the molecular heterogeneity of the syndrome.
Liddle’s syndrome mutations affect the cytoplasmic tail of ENaC subunits, altering or deleting a crucial PPPXY motif essential for interaction with WW domains of Nedd4-2 (and a homologue Nedd4-1) and degradation as well as for internalization via clathrin-coated pits (Schild et al. 1995). The mutated ENaC channel subunits in Liddle’s syndrome are no longer recycled, and the fraction at the luminal cell surface increases (Fig. 6). The ensuing constant inappropriate Na+ reabsorption causes volume expansion, even under conditions of high salt intake, and ultimately hypertension (Synder et al. 1995; Shimkets et al. 1997). A considerable genetic heterogeneity between different mutations and pedigrees has been observed. Since amiloride and triamteren specifically block ENaC channels, they are key treatment options to ameliorate symptoms in Liddle’s syndrome (Palmer and Alpern 1998).
As with the other forms of monogenic hypertension, it has been postulated that polymorphisms in ENaC genes could contribute to the pathogenesis of primary hypertension. The α-subunit (gene: SCNN1A) is located on the short arm of chromosome 12, a locus that has been linked to hypertension (Nagy et al. 1999; Disse-Nicodeme et al. 2000). Several common polymorphisms were identified in SCNN1A, among them a promoter polymorphism (G2139A) which was in close linkage disequilibrium to a 5′ UTR polymorphism in exon 1 in a large Japanese cohort (Iwai et al. 2002). The 2139G allele occurred in a frequency of ∼60%, and was associated with a higher SCNN1A promoter activity and hypertension, whereas the A allele appeared to protect against hypertension. While of potential interest, these results remain unconfirmed so far. For the SCNN1B gene a–comparably rare–T594M polymorphism located in the C terminus but unrelated to the crucial PPPXY motif has been identified that was more frequent in hypertensive (∼8% heterozygous carriers) than in normotensive (∼2%) blacks (Baker et al. 1998), results that were not reproduced in another black cohort (Nkeh et al. 2003; Hollier et al. 2006). A similar approach for the SCNN1G subunit resulted in the identification of a promoter polymorphism (G-173A) and a silent polymorphism in exon 3 with allele frequencies of ∼25% each (Persu et al. 1999; Iwai et al. 2001). The -173G allele was associated with a higher promoter activity and an increased risk for hypertension in the Japanese but not in the European sample. Interestingly, homozygous carriers of the -173A allele (occurring in only 0.7% of the population) had a higher prevalence of hypotension, and the mean systolic blood pressure was 11 mmHg lower, suggesting a function as a ‘hypotensive or hypertension protection gene’ here.
Independent genome-wide linkage analyses have identified a locus on chromosome 18q in primary hypertension. The Nedd4-2 gene localizes to chromosome 18q21-22. The gene extends over more than 400 kb and consists of at least 40 exons, which complicates genetic studies. So far, no linkage between blood pressure phenotypes and Nedd4-2 has been reported.
Gordon’s syndrome (pseudohypoaldosteronism type II)
Two splice variants of WNK1 have been identified that are controlled by different promoters, a full-length kinase-sufficient WNK1 trancript (L-WNK1), and a shorter isoform that lacks a functional kinase domain (KS-WNK1), which appears to be confined to the aldosterone-sensitive distal nephrone. L-WNK1 is involved in response to osmotic stressors, including hyper- and hypotonicity, while KS-WNK1 appears to regulate processes in aldosterone signalling. Activation of WNK4 is associated with a decreased incorporation of NCC into the membrane. In contrast, activation of WNK1 inhibits the WNK4-mediated suppression of NCC transporter translocalization (Fig. 8; Yang et al. 2003; Wilson et al. 2003) and requires kinase activity of WNK1.
The mutations found in the pedigrees described above cause either a large intronic deletion in the WNK1 gene that is associated with a fivefold increase in the expression of the L-WNK1 protein, or missense mutations in WNK4 (Wilson et al. 2001; Fig. 7). At first glance, gain-of-function by overexpression of L-WNK1 or loss-of-function of WNK4 both result in an increased membranal expression of NCC and an increased Na+ reabsorption in the distal tubule that causes hypertension. Inhibiting the NCC by thiazides is an effective remedy in this situation. The hyperkalemic metabolic acidosis is explained by the fact that less Na+ reaches the distal tubule / collecting duct where the concerted actions of ENaCs and ROMKs constitute a functional Na+ / K+ exchange. If less Na+ is reabsorbed, less K+ and H+ are lost to the urine, resulting in hyperkalemia and metabolic acidosis. A decreased insertion of ROMK into the membrane associated with mutated WNK4 further explains the observed hyperkalemia. On a molecular level, however, we have not yet understood the function of the WNK4 mutations for PHA2. Three of four identified PHA2B-causing WNK4 mutations are charge-changing substitutions (Glu562Lys, Asp564Ala; Gln565Glu) in an amino-acid motif localized directly adjacent to the first coiled-coil domain that is highly conserved in all members of the WNK family. An Arg1185Cys exchange also causes PHA2B. The affected Arg is located just distal of the second coiled-coil domain, and is also highly conserved in all WNK family members (Fig. 7; Wilson et al. 2001). Interestingly, all mutations are remote from the kinase domain. WNK4 kinase activity, however, is required for inhibition of NCC. Hence, the mechanism for the WNK4-mediated decrease in NCC surface expression is not understood. Current evidence suggests that it does not involve trafficking from ER to Golgi or clathrin-dependent internalization. The WNK4-mediated decrease in ROMK expression is mechanistically different since it does not require WNK4 kinase activity, and affects internalization via clathrin-coated pits. PHA2-causing WNK4 mutations cause greater (!) inhibition of ROMK than wild-type WNK4 itself. Available hypotheses view WNK4 (and the isoforms of WNK1) as partners of a multiprotein complex that involves the homo- and heteromultimers of WNKs that exert scaffolding and kinase functions on downstream target proteins. Mice bearing a transgene with the human PHA2-mutant WNK4 develop hypertension, hyperkalemia and hypercalciuria, with dramatic structural changes of the distal convoluted tubule, including hyperplasia and massive expression of NCC (Lalioti et al. 2006). This group suggested that PHA2B-causing mutations in negatively charged domains of WNK4 affect the ability to sense intracellular Ca2+ levels, e.g. in response to AngII, that are required for a functional fine-tuning of WNK4 and ultimately NCC activity. Given the heterogeneity of PHA2, the fact that the culprit gene for PHA2A on chromosome 1 has not been identified, and that PHA2 families are known with most likely mutations in yet other proteins, there is a good chance that additional players in this system must be identified for its full comprehension.
Changing from these molecular considerations to a systemic view of renal WNK-signalling, it appears that WNK1 and WNK4 are important switches for the control of renal sodium and potassium excretion. Adrenal aldosterone release is stimulated either by volume contraction or hyperkalemia, situations which require different adaptations (sodium and water uptake vs sodium uptake coupled to potassium excretion) of the kidneys despite an identical signal. WNK4 activity could be the switch for this adaptation (Lalioti et al. 2006).
In a genome-wide linkage analysis in the Framingham-Heart-Study population, a segment of chromosome 17 was identified that links to hypertension and contains the WNK4 gene (Levy et al. 2000). A G/A polymorphism in intron 10 of the WNK4 gene was identified, and found to occur in 13% vs 7% in white hypertensives and normotensives, a result that was not confirmed in later studies (Erlich et al. 2003; Speirs and Morris 2004; Tobin et al. 2005). In a hypertensive Japanese cohort, three novel missense mutations in the coding sequence of WNK4 were identified, but occurred altogether in only 5 of 956 patients (Kamide et al. 2004). For the WNK1 gene, a British survey with 712 severely hypertensive families detected no association of presumed WNK1 haplotypes with the risk for hypertension, but a significant association with a potential promoter polymorphism (rs1468326; minor allele frequency ∼10%) and the severity of hypertension (Newhouse et al. 2005). A population-based family study with 996 subjects from 250 white European families identified 9 SNPs in WNK1, and reported that five SNPs or their combinations and potential haplotypes were associated with blood-pressure parameters from 24-hr blood pressure recordings. These polymorphisms were confined to intron 1 (rs2369402, rs765250), intron 10 (rs880054), intron 22 (rs953361), intron 23 (rs2301880) and intron 26 (rs2286028), and the minor allele frequencies ranged from 10–40%. It should be noted that the above rs1468326 SNP was not associated with hypertension in this survey (Tobin et al. 2005). In conclusion, the identification of WNK1 and WNK4 5 years ago has sparked a whole new research in the fine regulation of renal Na+ and K+ handling, and has expanded our understanding of kidney physiology. Further studies are required to unravel potential contributions to the genetics of essential hypertension.
Autosomal dominant hypertension with brachydactyly
While the monogenic forms of hypertension presented so far affect renal Na+ and volume control, either by affecting Na+ transporting systems of by interfering with signal transduction systems or the function of the mineralocorticoid receptor, autosomal dominant hypertension with brachydactyly is different. This syndrome was described in a large Turkish pedigree, and includes severe hypertension and strokes in early life as well as brachydactyly (shortened fingers) and short stature (Bilginturan et al. 1973). Luft and co-workers meticulously characterized these patients. Parameters of kidney function (renin, angiotensin II, aldosterone levels), the activity of the autonomous system (catecholamine responses) are in the normal range (Schuster et al. 1996a), and the patients exhibit no characteristic susceptibility towards a specific class of five tested classes of antihypertensives (Schuster et al. 1998).
With respect to an initial finding of a looping vessel in cerebral arteriography in one patient, cranial MRI suggested that 15 affected family members had signs of neurovascular compression, in contrast to 12 non-affected relatives. In the affected subjects, unilateral or bilateral loops of the vertebral artery or the posterior inferior cerebellar arteries were detected (Naraghi et al. 1997). Various neurosurgical, neuroanatomical and neuroradiological studies document that neurovascular abnormalities in the posterior fossa of the skull can result in compression of the ventrolateral medulla near the entry zones of the cranial nerves IX and X. A postulated hyperactivation of medullary autonomus structures may ultimately cause hypertension (Janetta et al. 1985; Naraghi et al. 1994).
Based on a hypothesis of autonomous hyperactivity, in-depth analyses of vegetative functions were conducted in affected patients with brachydactyly and hypertension. Complete ganglionic blockade did not reduce hypertensive blood pressure values in young affected family members, suggesting that autonomic activity is not responsible for increases in basal blood pressure (Jordan et al. 2000). Likewise, muscle sympathetic nerve activity during sympathetic stimulation was not different or even lower at rest and upon stress testing in affected subjects, arguing against an increased sympathetic nerve activity. Sympathetic stimuli including cold pressure, handgrip testing and upright posture, however, caused excessive increases in blood pressure in affected subjects. Similarly, the potency of the non-selective α-adrenoceptor-agonist phenylephrine to increase blood pressure was more than an order-of-magnitude higher in the affected family members. Since the relative sensitivity to phenylephrine was distinctly reduced in these patients during ganglionic blockade—which also blocks the baroreceptor reflex—the authors concluded that an impaired ability of the baroreceptor reflex to compensate increases in blood pressure is a crucial abnormality in this type of monogenic hypertension (Jordan et al. 2000).
Another total genome analysis in pedigrees with familial hypertension from a Chinese geographic isolate revealed a significant linkage of the hypertensive trait (without brachydacytly) again to chromosome 12p (Gong et al. 2003), indicating that brachydactyly and hypertension are most likely caused by different genes on chromosome 12p, obviously co-localizing in the Turkish kindred. Subsequent high-resolution cytogenetic analyses of the Turkish kindred revealed a 3.5 Mbp intrachromosomal rearrangement on chromosome 12p that included among uncharacterized genes the genes for the ATP-dependent potassium channel Kir6.1 (KCNJ8), the regulator of the sulfonyl urea receptor SUR2 (ABCC9) and the phosphodiesterase PDE3A as reasonable targets for blood pressure increases. Gene expression studies and pharmacological in vivo characterizations of these candidate genes, however, revealed no consistent differences between affected and non-affected family members (Fig. 9; Bähring et al. 2004).
What we measure as blood pressure is a highly regulated value, the final integration of blood pressure elevating and lowering effects. To comprehend genetic mechanisms causing hypertension, it is rewarding to face also the ‘hypotensive arm’ of blood pressure control. Having understood the known ‘knowns’ of monogenic hypertension, it is not surprising that mutations with opposite cellular effects in such genes (e.g. loss-of-function instead of gain-of-function) finally cause monogenic hypotension.
Defective mineralocorticoid action and pseudohypoaldosteronism type I
Mineralocorticoid-stimulated Na+ reuptake is critical for volume control, and we have learned that increased mineralocorticoid activity causes volume expansion and hypertension, as shown for GRA or AME. As a mirror image, patients with inborn errors in the biosynthesis of aldosterone present with salt wasting, severe hypotension, and a decreased distal tubular K+ and H+ secretion. Well-characterised syndromes include homozygous loss of aldosterone synthase activity (the actual mirror image of GRA) or 21-hydroxylase activity (Mitsuuchi et al. 1992; Pascoe et al. 1992b; Bongiovanni and Root 1963; Armor et al. 1988).
Similar syndromes arise if the mineralocorticoid receptor is inactive (Fig. 4). These syndromes, termed pseudohypoaldosteronism type I (PHAI), include life-threatening neonatal hypotension, dehydratation and salt wasting, accompanied by hyperkalemia, metabolic acidosis and grossly increased aldosterone levels. Autosomal dominant and recessive forms of PHAI have been identified (Hanukoglu 1991). The autosomal dominant types result from loss-of-function mutations in one MR gene (Geller et al. 1998), which indicates that two functional copies of the MR gene are necessary for regular salt homoeostasis. Salt-rich diets ameliorate the symptoms, and the syndrome itself attenuates with age, nicely illustrating the close interactions of genetic, demographic and environmental factors in blood pressure control.
Bartter’s and Gitelman’s syndromes
Gitelman’s syndrom is the result of a wide variety of loss-of-function mutations in the thiazide-sensitive Na+/Cl+ transporter (Fig. 12; Simon et al. 1996a). NCC in the distal convoluted tube governs the reabsorption of approximately 7% of Na+. Hence, symptoms in Gitelman’s syndrome are less severe than in Bartter’s syndrome, and include hypokalemia, metabolic alkalosis, hypomagnesemia and hypocalciuria (in strict contrast to hypercalciuria in Bartter’s syndrome) in addition to low normal blood pressure or overt hypotension, mirroring the situation of extensive thiazide diuretics intake. Patients typically present with non-specific neuromuscular signs in adolescence or young adulthood (Bettinelli et al. 1992). The tubular loss of salt is counterbalanced by an activation of the renin-angiotensin-aldosterone system that leads to increased Na+ reabsorption via ENaC channels in the cortical collecting duct, at the expense of enhanced K+ and H+ excretion. Heterozygous carriers of these mutations are normotensive but do actually consume more salt, again underscoring the tight interaction of genetic and environmental factors to blood pressure regulation. While homozygous carriers of Gitelman’s or Bartter’s mutations suffer from severe disorders, there is speculation that heterozygotes or carriers of other mutations that cause only mild inhibition of such transporters are protected against hypertension (Cruz et al. 2001). In addition to this considerable number of loss-of-function mutations in these ion transport proteins, a gain-of-function mutation in CLCNKB has been reported that causes a conservative amino acid substitution (T481S; Fig. 11). It occurs in 12% of white Europeans and 22% of black Africans (Jeck et al. 2004). In one study, hypertension frequency increased from 25% in carriers of the wild-type gene to 45% in carriers of the mutation, findings that were not confirmed by other groups (Jeck et al. 2004; Kokubo et al. 2005; Speirs et al. 2005).
So far, we have discussed monogenic forms of arterial hypertension and hypotension. Interestingly, almost all genetic abnormalities relate to renal salt and water handling. It is tempting to speculate that, for polygenic hypertension, genetic abnormalities in renal mechanisms may also exert key effects. Furthermore, we are at the beginning of investigating whether common polymorphisms in these genes have an impact on polygenic hypertension.
Polygenetic forms of hypertension
In contrast to the rare cases of monogenic hypertension, primary hypertension is attributable to polygenetic mechanisms, a mosaic of neural, hormonal and cellular abnormalities with a strong influence of lifestyle and environmental factors. There is evidence that the impact of certain genetic polymorphisms varies between major ethnicities. Within the last decade, numerous genes have been implicated in the genetics of hypertension, in many cases with a narrow basis of evidence only. Here, we focus on several hypertension candidate genes for primary hypertension, for which a considerable amount of knowledge on potential pathomechanisms exists in addition to linkage analyses or association studies.
Components of the renin-angiotensin-aldosteron system
Given the pivotal role of the renin-angiotensin-aldosteron (RAS) system for long-term regulation of blood pressure and volume and as drug targets in the treatment of hypertension, it was obvious to consider RAS components as candidate genes in hypertension. Under conditions of reduced renal perfusion pressure, salt or volume losses or sympathetic activation, renin, an aspartyl protease, is released from juxtaglomerular cells in the kidney. It cleaves the inactive peptide angiotensinogen (AGT), synthesized in the liver, into angiotensin I, which is converted into angiotensin II (Ang II) by the converting enzyme (ACE). AngII binds to its specific G protein-coupled receptor (GPCR) on vascular smooth-muscle cells to cause potent vasoconstriction, and in the adrenal glomerulosa to induce mineralocorticoid secretion. Vasoconstriction and aldosterone-mediated sodium reabsorption counteract the initial fall in renal perfusion pressure.
Polymorphisms in the angiotensin converting enzyme
While most authors have ruled out linkage between hypertension and the ACE gene (Jeunemaitre et al. 1992a; Schmidt et al. 1993; Schunkert et al. 1994; Iwai et al. 1994; Vasku et al. 1998; Tiret et al. 1998; Castellano et al. 2003), others have reported significant associations between this polymorphism and hypertension in certain subgroups, e.g. males (Fornage et al. 1998; O’Donnel et al. 1998; Kario et al. 1999; Giner et al. 2000). A first meta-analysis based on 28 case-control studies with 6923 individuals revealed a non-significant pooled odds ratio for hypertension in carriers of the DD versus II genotypes, translating into a 10% increased risk for hypertension in carriers of the DD genotype. Subgroup analyses indicated a significantly increased hypertension risk for women and in Asians (Staessen et al. 1997), contrary to studies mentioned above. A more recent meta-analysis in 15,942 Caucasians indicated that the attributable blood pressure increase for carriers of the DD genotype amounted to 0.5 mmHg (95% CI: −0.5–1.8) compared to the II genotype (Agerholm-Larsen et al. 2000). Another recent review counted 12 positive and 14 ‘negative’ publications on this issue (Agarwal et al. 2005). Likewise, available evidence suggest that the D allele causes a modest–and most likely irrelevant–increase in the risk for other cardiovascular and renal diseases (Cambien et al. 1992; Schunkert et al. 1994; Iwai et al. 1994; Pontremoli et al. 1996; Fernandez-Llama et al. 1998). For these entities, meta-analyses revealed odds ratios for carriers of the DD genotype ranging from 1.04–1.43 for myocardial infarction (Agerholm-Larsen et al. 2000; Keavney et al. 2000) and from 1.28–1.56 (Staessen et al. 1997; Ng et al. 2005) for diabetic nephropathy.
Polymorphisms in the angiotensinogen gene
The M235T polymorphism in the AGT gene was the first and the most scrutinized candidate linked to essential hypertension. It is in linkage disequilibrium with a T174M polymorphism, also frequently addressed. Available evidence suggests that the T allele of the M235T variant is associated with higher circulating angiotensinogen levels (∼20% in homozygous carriers) and increased blood pressure and preeclampsia (Jeunemaitre et al. 1992b; Ward et al. 1992; Staessen et al. 1999). Some animal models indicate that increased AGT gene expression results in hypertension (Takahashi and Smithies 1999). AGT belongs to the serpin gene superfamily and is expressed in many tissues, including liver, heart, adipose tissue, vessel wall, brain and kidney. The AGT gene comprises ∼12 kb on chromosome 1 and contains 5 exons (Fig. 13). AGT expression is controlled by a 1.2-kb promoter region, and further augmented by an enhancer immediately downstream of a second polyadenylation site in the 3′ flanking region. The sole exchange of methionine by threonine at position 235 is not a likely mechanism causing hypertension. This exchange is located distantly from the renin cleavage site, and in vitro renin-mediated AngI generation is kinetically not different for the 235T variant. Currently, a promoter polymorphism at position -6 (G-6A) in strong linkage disequilibrium (-6G–235M; -6A–235T) is a more plausible candidate for differing AGT transcriptions (Inoue et al. 1997; Morgan et al. 1997). Many additional polymorphisms, however, have been identified in the AGT gene, including an additional promoter polymorphism at −20. This polymorphism is also interesting, since depending on the genotype different response elements are generated, including those for estrogen receptor α, upstream regulatory factor and members of the COUP-TF family, which correlates with different phenotypes, including pregnancy-dependent variations in AGT levels, non-modulating hypertension and an altered relationship between BMI and blood pressure (Zhao et al. 1999; Morgan et al. 2000; Hilgers et al. 2001; Tiago et al. 2002). Current research efforts address the haplotype structure of the AGT gene, which should be comparatively easy given the short length of the gene of only ∼12 kb. Based on the number of SNPs included in each definition of haplotypes and by the ethnicities analysed, haplotype maps vary markedly. While some reports showed that defined haplotypes contribute to the risk for hypertension (in part modulated by polymorphisms at the ACE locus), others found contrasting results. Available evidence suggests that there are more than five common haplotypes of the AGT gene that include promoter, coding region and 5′ flanking region polymorphisms (Jeunemaitre et al. 1997; Nakajima et al. 2002; Brand et al. 2002; Zhu et al. 2003a,b; Tsai et al. 2003; Gu et al. 2005). While genetic concepts promise that understanding haplotype structures will reduce complexities, at present this is not the case for the AGT locus, and we have to await further clarification of this issue.
For the common AGT M235T polymorphism, more than 500 reports exist that address hypertension and other cardiovascular diseases. Both positive and negative associations were documented for white populations in North America, Australia, Japan, Europe, and China, while no associations were reported from black populations in the Caribbean, USA and Africa (Jeunemaitre et al. 1992b; Caulfield et al. 1994, 1995; Hata et al. 1994; Kunz et al. 1997; Staessen et al. 1999). Meta-analyses confirmed the association between the 235T allele with hypertension in whites, potentially Asians but not in blacks, with significant odds ratios ranging from 1.22–1.60 (Kunz et al. 1997; Staessen et al. 1999; Kato et al. 1999; Sethi et al. 2003). The absolute effect, however, is rather modest, best illustrated by the Italian GENIPER study on 2,461 subjects; this study reported significant odds ratios of 1.35 for hypertension in carriers of the 235T allele, but the absolute blood pressure difference between genotype groups was smaller than 1 mmHg (Castellano et al. 2003).
Genetic variants in the angiotensin II receptor type I
Since AngII-mediated vasoconstriction and aldosterone secretion are mediated by the angiotensin II receptor type 1 (AT1R), several groups searched for common polymorphism in its gene, which comprises more than 55 kb and consists of 5 exons. These efforts resulted in the identification of an A1166C variant that is confined to the 3′ untranslated region of the AT1R cDNA (Bonnardeaux et al. 1994; Wang et al. 1997) and has been implicated in determining mRNA stability and, ultimately, receptor expression (Thekkumkara and Linas 2003; Fig. 13). There is evidence that a 3′-UTR motif of the receptor mRNA involving bases 2179–2195—i.e., far downstream of the A1166C polymorphism—is essential for the binding of regulatory proteins including calreticulin. AngII-stimulated phosphorylation of calreticulin has been demonstrated to increase AGT1R mRNA decay (Nickenig et al. 2001, 2002). It has also been proposed that removal of the entire 3′-UTR from the AT1R changes the coupling of the AT1R from Gαi to Gαq. However, the mechanisms for such an astonishing observation have remained obscure to date (Thekkumkara and Linas 2003). Furthermore, a role for the receptor’s 3′-UTR in tachyphylaxis of AngII-induced inositol trisphosphate and Ca2+ levels has been suggested (Franca et al. 2003). While these novel mechanisms of posttranscriptional mRNA processing are highly interesting, there are no convincing connections of these observations to the A1166C polymorphism.
Several reports have shown an association between the AT1R 1166C allele and hypertension, especially severe hypertension (Bonnardeaux et al. 1994; Hingorani et al. 1995; Wang et al. 1997; Kainulainen et al. 1999; Henskens et al. 2003) and in pregnant women (Nalogowska-Glosnicka et al. 2000; Kobashi et al. 2004). Other groups refuted these results (Schmidt et al. 1997; Zhang et al. 2000; Staessen et al. 2001; Iliadou et al. 2002; Ono et al. 2003). Overall, it remains open whether there is a relevant association between the AT1R A1166C polymorphism and hypertension. Furthermore, the suggested pathoetiology of this silent nucleotide exchange is at best uncompletely understood.
Meanwhile, more than 55 additional SNPs have been identified in the AT1R gene, and there is some evidence for linkage between the A1166C and an A-153G promoter polymorphism (Takahashi et al. 2000; Lajemi et al. 2001). From clinical studies, it has been suggested that homozygous carriers of the 1166C allele exhibit lower decreases in blood pressure (2 mmHg) than homozygous carriers of the 1166A allele (12 mmHg) upon administration of AT1R blockers in a setting of high salt diet (Spiering et al. 2000, 2005). Another group did not observe physiological differences upon AngII infusion between carriers of the various AT1R A1166C genotypes who were on a normal salt diet (Hilgers et al. 1999).
While components of the RAS are obvious candidate genes for hypertension research, we have to conclude after many studies that the contribution of known variations in these genes to the observed blood pressure variation is modest, if present at all. The reason for this sobering notion is most likely that we deal with a highly regulated system. From the many genetically engineered mouse models of the RAS, it appears that just changing the expression levels (the suggested mechanisms of the common RAS polymorphisms in man) of RAS components (as exemplified by 1, 2, 3 or 4 ACE genes) does not change blood pressure (or only modestly), as long as the secretion of renin (and other pressure regulating systems) is adapted to this situation. Only in situations when the regulatory balance is hampered (e.g. in diabetes) do such mice develop a pronounced phenotype (Bernstein et al. 2005), a situation in some agreement with observations in man.
Polymorphisms in adducin genes
A manifold of animal models for various aspects of hypertension have been inbred or generated by direct transgenic manipulations. The identification of the α-adducin gene is the sole example that discoveries in animal studies have directly resulted in the identification of genetic polymorphisms in man. Crucial for the identification of α-adducin polymorphisms was the generation of hypertensive and normotensive rat strains by classical selection and crossing experiments leading to the Milan hypertensive (MHS) and normotensive (MNS) strains. Refined physiologic analyses of these animals revealed that prehypertensive young MHS animals exhibited—among other features—an increased glomerular filtration rate, an enhanced 24-hr Na+ urinary output and a reduced plasma renin activity (Ferrari and Bianchi 1995), a phenotype also observed in some young human individuals prone to develop hypertension (Cusi and Bianchi 1996). The further development of hypertension in MHS is accompanied by an increased renal Na+ reabsorption. Na+ transport abnormalities were also detected in erythrocytes (but not erythrocyte membranes) from MHS, findings that sparked cross-immunization experiments between MHS and MNS. Raised antibodies detected adducin, which is ubiquitously expressed and found in erythrocytes in considerable amounts. Adducin is a heterodimeric cytoskeleton protein that consists of an α-subunit (103 kDa) and either a β-subunit (97 kDa) or a γ-subunit (90 kDa) encoded by three different genes referred to as Add1, Add2 and Add3. They sustain spectrin–actin binding, and control as end-capping actin proteins the rate of actin polymerization and, thus, the organization of the spectrin-actin lattice. This activity of adducin is further regulated by Ca2+/calmodulin and the kinases PKA, PKC and Rho-kinase (Matsuoka et al. 2000).
Systematic sequence analyses of the adducin genes in MHS and MNS led to the identification of polymorphisms in the rat α-adducin (Add1, F316Y), β-adducin (Add2, Q529R) and γ-adducin (Add3, Q572K), that segregated in part with the hypertensive trait (Bianchi et al. 1994; Tripodi et al. 1997). Backcross experiments indicated that the Add1 F316Y polymorphism (but not the variants in Add2 and Add3) accounted for about 50% of the blood pressure variation in the F2 hybrid population (Bianchi et al. 1994). Furthermore, reciprocal gene transfer of the α-adducin chromosomal region modulated the pressure of MHS and MNS strains (Tripodi et al. 2004).
An intensive search for similar polymorphisms in humans resulted in the identification of two common polymorphisms (G460W [rs4961], S586C [rs4963]) in the human α-adducin gene (Add1; Cusi et al. 1997). Additional polymorphisms were identified in all three human adducin genes. At present, most studies were conducted with the G460W polymorphism, which has been shown to be associated with increased blood pressure in case-control and linkage studies (Cusi et al. 1997). It is worthy of note that the human Add1 G460W exchange is not homologous to the F316Y exchange in rats. Hence, it is important to distinguish biochemical and physiological effects observed within different species. Many studies following these initial observations have addressed the potential association of the α-adducin 460W allele with hypertension and other cardiovascular diseases. As with many association studies, results were variable and in part contradictory, attributed partially to confounders of ethnicity, lifestyle and other environmental factors (reviewed in Bianchi et al. 2005). Hence, some family studies showed associations between adducin alleles and blood-pressure parameters or demonstrated linkage with the α-adducin locus, while others failed to do so (Cusi et al. 1997; Niu et al. 1999; Chu et al. 2002; Ju et al. 2003; He et al. 2003; Wang et al. 2004). Similarly, the majority of studies addressing blood pressure in general, predominantly normotensive populations failed to show associations with adducin polymorphisms, reported positive associations for subgroups only (e.g. postmenopausal women), or depended on epistatic interactions with other polymorphisms, especially the ACE I/D polymorphism. Eleven case-control studies demonstrated a positive association between adducin polymorphisms and hypertension, whereas 12 studies reported contradictory results (reviewed in Bianchi et al. 2005). Carriers of the 460W allele reportedly have lower renin levels and a larger decrease in blood pressure upon administration of diuretics (Glorioso et al. 1999). At the cellular level, hypertensive carriers of the 460W allele are characterised by a decreased red cell Na+ content and an increased Na+/K+ transport (Glorioso et al. 2002). For the human Add2 C1967T polymorphism, evidence for an association between the 1967T allele and increased blood pressure in a high salt intake population exists (Tikhonoff et al. 2003).
Interestingly, the p85 subunit of PI3 kinase can also directly interact with the Na+/K+ ATPase (Chibalin et al. 1998; Yudowski et al. 2000). Adaptin binds to cargo proteins, recruits clathrin and promotes the formation of clathrin-coated pits (Kirchhausen 2000), triggering an endocytotic process of the Na+/K+ ATPase that reduces sodium pump activity in the kidney and causes a decreased Na+ reabsorption upon dopamine stimulation.
Early transfection studies with the mutant rat α-adducin (316Y) into renal cells revealed a rearrangement of the cytoskeleton (potentially by an accelerated actin polymerization) associated with an increased Na+/K+ ATPase activity (Tripodi et al. 1996). More recently, expression of rat and human α-adducin variants has been implicated in a reduced endocytosis of Na+/K+ ATPase molecules (Efendiev et al. 2004). Stimulation with dopamine resulted in phosphorylation and internalization of Na+/K+ ATPase subunits, an effect that was blunted in the presence of variant α-adducin subunits (Fig. 14). The reduced internalization was accompanied by a decreased phosphorylation of adaptin (or more accurately, of its μ2 subunit) which governs the affinity for binding to cargo proteins (Efendiev et al. 2004). Although these findings have remarkably extended our knowledge concerning the molecular pathology of α-adducin variants, many questions remain open. It is completely unknown where α-adducin, the actin-cytoskeleton and the dopamine-mediated mechanisms of adaptin- and clathrin-dependent Na+/K+ ATPase internalization meet. In non-stimulated renal epithelial cells expressing the rat α-adducin variant, adaptin phosphorylation status was increased despite reduced Na+/K+ ATPase internalization. This puzzling result was interpreted as a defect in the transition of phosphorylated to unphosphorylated adaptin, caused by a protein phosphatase that is part of a complex with adducin. Complexation of such a protein phosphatase with adducin and the cytoskeleton, required for proper phosphorylation / dephosphorylation of adaptin, may be disturbed in adducin mutants (Efendiev et al. 2004). Further studies are required to resolve these questions and to explain why the proposed internalization abnormality is confined to the Na+/K+ ATPase and does not occur in other membrane proteins, e.g. the dopamine or Ang II receptor as shown in this report (Efendiev et al. 2004). It remains open how these mechanisms that affect the dynamics of Na+/K+ membrane expression are in accordance with results from another study suggesting that the kinetic activity of the Na+/K+ ATPase is increased and its ATP affinity is higher in the presence of the rat 316Y and the human 460W variants compared to wildtype α-adducin in cell-free preparations (Ferrandi et al. 1999).
In summary, we have to conclude that numerous reports describe abnormalities in cellular and renal Na+ handling, renin-angiotensin status, efficacy of diuretics and in blood pressure control in carriers of the Add1 460W allele, although many contradictory findings exist. We begin to understand how mutants in α-adducin may affect the internalization of the Na+/K+ ATPase. Nevertheless, many questions remain open related to the tissue-specific expression of the adducin heterodimers, potential splice variants, the haplotype blocks within the adducin genes and the blood pressure control in adducin knock-out and knock-in models.
Polymorphisms in G protein-coupled receptor signalling mechanisms
According to biophysical concepts, primary hypertension is basically characterized by an increased peripheral resistance, which reflects an altered balance between vasoconstriction and vasodilation. Therefore, hormones and signalling mechanisms that regulate vascular tone have gained interest as candidate genes by many workers in the field of hypertension genetics.
G protein-coupled receptors are a huge family of membrane receptors that comprise more than 3% of all genes in our genome. In the cardiovascular system, typical GPCRs are the α- and β-adrenoceptors, receptors for endothelins, angiotensin II, vasopressin and many other agonists.
Genetic variants in β-adrenoceptor genes
A Scandinavian sib and case-control study documented that homozygous carriers of the 389Arg allele, i.e., those with improved coupling to G proteins, had significantly higher diastolic blood pressure and heart rates. Odds ratios for hypertension in this cohort amounted to 1.9. The Ser49Gly polymorphism, however, did not affect blood pressure (Bengtsson et al. 2001a,b). In Caucasians, but not in other ethnicities, this result has been confirmed once (Humma et al. 2001) and contradicted by other investigators (Büscher et al. 2001; Ranade et al. 2002; O’Shaughnessy et al. 2000; Sofowora et al. 2003).
The β2 adrenoceptor (β2AR) is also encoded by an intronless gene, located on chromosome 5. Upstream of its coding region is the coding region for a 19 amino acid peptide, termed 5′ leader cistron, that has been implicated in receptor expression. Since blunted β-adrenoceptor-mediated vasodilation has been observed in hypertension, the β2AR has become a candidate gene for this disease (Stein et al. 1995). To date, several polymorphisms have been identified in the β2AR, five of which change the primary sequence (Fig. 15). A Val34Met polymorphism (in the first transmembrane domain) occurs rarely, and the Cys(-19)Arg affects the 5′ leader cistron. The Arg16Gly, Gln27Glu and Thr164Ile polymorphisms have been frequently investigated. These polymorphisms display marked linkage disequilibirum, which results in the occurrence of three dominant haplotypes: -19Arg/16Gly/27Glu, -19Cys/16Gly/27Gln and -19Cys/16Arg/27Gln (Wang et al. 2001). Functional analysis revealed that the Arg16Gly and the Gln27Glu polymorphisms, located in the amino-terminus of the protein, neither alter ligand binding nor adenylyl cyclase activity (Green et al. 1994). The 16Arg and the 27Glu forms of the receptor, however, were resistant to agonist-promoted down regulation upon individual expression in in vitro studies (Green et al. 1994). In double-mutation studies, however, the 16Gly mutation confered a dominant phenotype over the 27Glu variant, while the 16Arg/27Glu variant (the frequency of which in the population is <1%) was completely resistant to down-regulation (Green et al. 1994). In vivo the situation becomes more complex, and the 16Gly has also been linked to reduced (!) desensitization. For the 164Ile variant of the Thr164Ile polymorphism located in the fourth transmembrane domain, considerably lower affinities for isoproterenol, epinephrine and norepinephrine associated with decreased basal and agonist-stimulated adenylyl cyclase activity have been documented (Green et al. 1993). Finally, carriers of the -19Cys allele in the 5′ cistron have been reported to express significantly more β2AR (McGraw et al. 1998).
Potential associations between β2AR polymorphisms and hypertension were addressed in the Rochester Heart Study, which included 55 pedigrees with at least one discordant sib pair and 589 different families, to elucidate a region on chromosome 5 (including the β2AR gene) which was formerly linked to hypertension. They found that the 16Gly and 27Glu alleles were more common among hypertensives than the 16Arg and 27Gln alleles. The β2AR polymorphisms accounted for ∼2% of the observed variation in blood pressure (Bray et al. 2000). While results of some groups confirmed the association between the 16Gly allele and blood pressure (Kotanko et al. 1997; Rosmond et al. 2000; Gratze et al. 1999), others found opposite effects, i.e., an association between the 16Arg allele and hypertension (Busjahn et al. 2000; Bengtsson et al. 2001a,b; Timmermann et al. 1998) or no effects at all (Herrmann et al. 2002; Kato et al. 2001; Xie et al. 2000; for a recent meta-analysis see Hahntow et al. 2006). Again, differing inclusion of haplotypes, variations in ethnicities and different study designs may contribute to these sobering results. Although β1ADR und β2ADR genes may affect blood pressure regulation, the actual contribution of genetic polymorphisms in these genes appears to be small, if present.
Genetic variants in the gene for the Gα subunit (GNAS) and the gene for the Gβ3 subunit (Gβ3)
Since both β adrenoceptors couple to GαS, the GNAS gene became an interesting candidate gene in hypertension research. Loss-of-function and gain-of-function mutations in the GNAS gene cause complex phenotypes involving bone Ca2+ homoiostasis and mesenchymal growth abnormalities, leading to rare diseases which include McCune-Albright osteodystrophy or pseudohypoparathyroidism types Ia and Ib. The GNAS locus, located on chromosome 20q, is subject to a highly complex regulation, and it is partially imprinted in different tissues (for review see Weinstein et al. 2006). Jia et al. (1999) detected a silent polymorphism in exon 5 of GNAS (T393C), and documented an association between increased systolic blood pressure and the 393T allele. Carriers of the 393T allele were more frequently classified as poor responders upon treatment with betablockers (Jia et al. 1999). So far, no mechanistic explanation for this polymorphism has been provided, and information on GαS expression or function is completely lacking. The effect of this polymorphism on hypertension was addressed in three Japanese studies. While no or only modest associations were documented, those studies suggested considerable environmental influences, and reported an enhanced hypertension risk for carriers of the 393T allele in non-heavy smokers (Abe et al. 2002) and in heavy consumers of alcohol (Chen et al. 2003; Yamamoto et al. 2004). It is astonishing that further epidemiologic, genetic and biochemic evidence is lacking for this variant, given the well-established methods for assaying G protein expression and function.
Based on results that G protein-mediated signaling is enhanced in a subgroup of hypertensive patients, and that this phenotype is retained under cell culture conditions (Rosskopf et al. 1993), a systematic sequencing strategy resulted in the discovery of a silent polymorphism in GNB3 (C825T), the gene for the Gβ3 subunit (Siffert et al. 1998). This gene is located on the short arm of chromosome 12, which has frequently been implicated as a hypertension locus, although current evidence suggests that the different loci do not completely overlap (Fig. 9). Mechanistically, this polymorphism is associated with the occurrence of two alternative splice variants termed Gβ3s and Gβ3s2 (Fig. 16; Siffert et al. 1998; Rosskopf et al. 2003a). Protein crystallization studies have resolved the structure of the Gβγ dimer. The Gβ protein consists of seven regular protein motifs which are called WD domains. These seven domains, which are highly conserved in all eukaryotes, form a propeller protein that exhibits a very compact and stable structure which allows Gβ proteins, as other WD proteins, to assemble and coordinate multi-protein complexes, which is the way in which Gβγ dimers regulate effector systems. The splicing to Gβ3s or Gβ3s2 causes the loss of the equivalent of one WD domain upon translation of such transcripts (Fig. 16). It is difficult to explain how the loss of one WD domain translates into the gain-of-function of the system. One theory suggests that Gβγ dimers containing Gβ3s or Gβ3s2 are less suited to stabilize–as a heterotrimer–a Gα subunit in its GDP-bound form. This could result in an increased sensitivity of such a heterotrimer towards activation by a receptor. Although these concepts contain some plausibility, a final conclusive proof is missing. Overexpression of Gβ3s or Gβ3s2 in different cell types and model systems mimics some of these issues, while other features are missing, e.g. the activation of certain effector systems by Gβ3s or Gβ3s2 (Rosskopf et al. 2003a,b; Ruiz-Velasco and Ikeda 2003). Overexpressing G protein components into cell lines is on the one hand a routine method for the analysis of this system, but bears some problems because it grossly disturbs a fine-controlled balance of endogenous G protein signaling components. Presently, we have to conclude that–despite considerable efforts–the molecular process by which a polymorphism in GNB3 translates into a complex phenotype is yet unresolved, which contrasts with the considerable amount of data from genetic association studies.
Given that the 825T allele of the mentioned GNB3 C825T polymorphism actually sensitizes signal transduction in all cell types where Gβ3 is expressed, it is easy to speculate that an enhanced signal transduction may affect vessel reactivity, the activity of the vegetative nerve system or the signaling by vasoactive agonists including angiotensin II or endothelins. This could ultimately result in hypertension. Again, a final proof for these concepts is missing.
Several groups have reproduced the original finding that the GNB3 825T allele is associated with hypertension, whereas other groups refuted that finding (Siffert et al. 1998; Schunkert et al. 1998; Benjafield et al. 1998; Brand et al. 1999; Dong et al. 1999, to cite but a few). The fact that there is a considerable variance in genotype distribution within different ethnicities (Siffert et al. 1999) creates a major problem. While the C allele is the predominant allele in Caucasians, in blacks the T allele prevails. Asians have intermediate frequencies. Hence, there is a high risk for disparate population admixture in case-control studies. The GNB3 gene comprises a comparably short stretch of 6 kB DNA on chromosome 12. This explains why in Caucasians two haplotypes explain more than 95% of the observed variability (Fig. 16; Rosskopf et al. 2000, 2002). In other words, genotyping at the C825T locus provides information for six additional tightly linked polymorphisms. In Asians and in blacks the situation is more complicated. Since we do not know which of the identified polymorphisms are ultimately necessary for alternative splicing to Gβ3s or Gβ3s2, different ethnic-dependent haplotype structures could be one solution to some discrepancies observed.
The 825T allele has also been linked to obesity, and speculations were raised whether this polymorphism contributes to the pathogenesis of a metabolic syndrome (Siffert et al. 1999). While considerable controversy on certain issues remains, the different alleles of the GNB3 C825T polymorphism are obviously associated with complex phenotypes. Some results in this field are promising; nevertheless, many questions regarding the mechanisms remain not yet understood.
Genetic variants of the regulator of G protein signalling (RGS2)
RGS2 is expressed among other tissues in heart, vascular smooth-muscle cells, in the kidneys and in the brain. While RGS2 can act as a GAP protein for Gαi and GαS proteins (Ingi et al. 1998; Sinnarajah et al. 2001), it is the most potent RGS for Gαq, the Gα subunit pivotal for the signalling of most vasoconstrictors, including noradrenaline, AngII, endothelin-1, thromboxane, vasopressin and thrombin (Heximer et al. 1997). RGS2 will not only attenuate Gαq-mediated vasoconstrictor signals, vasoconstrictors such as AngII can also stimulate RGS2 transcript expression, which will ultimately result in a further feedback inhibition of Gαq-mediated signals (Grant et al. 2000). In line with these findings, RGS2 knock-out mice exhibit increased and protracted vasoconstriction, severe hypertension and vascular hypertrophy, already in the heterozygous state (Heximer et al. 2003). Unexplained so far remain the facts that these mice did not develop pronounced cardiac hypertrophy, and that pressor responses to common agonists including AngII and noradrenaline were distinctly blunted. Abnormalities in renal sodium handling have not been observed in these animals.
Another fascinating discovery was that RGS2 is an integrator making two different worlds of cell signalling meet: GPCRs and NO-mediated signalling. NO, released from endothelial cells is known to stimulate cGMP production in vascular smooth-muscle cells via a soluble guanylyl cyclase. cGMP in turn stimulates a cGMP-dependent protein kinase, PKGI-α, that is supposed to further relay the vasodilatory signal to target proteins. Tang et al. (2003) identified RGS2 as a substrate of PKGI-α, and showed that PKGI-α-mediated phosphorylation of RGS2 results in an increased GAP activity and ultimately in the inhibition of Gαq-mediated vasoconstrictor signals (Fig. 17). In addition, the N-terminus of RGS2 can bind to and inhibit type V adenylyl cyclase (Salim et al. 2003). GPCRs themselves have become partners for RGS2 interaction, as shown recently for the α1A adrenoceptor, potentially by interaction of the N-terminal domain of RGS2 with the third intracellular loop of GPCRs mediated by the protein spinophilin in a Ca2+ sensitive fashion (Fig. 17; Bernstein et al. 2004; Hague et al. 2005; Wang et al. 2005). Apart from the cardiovascular functions mentioned so far, RGS2 activity has also been implicated in the regulation of immune functions and neuronal plasticity.
Altogether, these fascinating new findings make RGS2 a prime candidate in the search for hypertension candidate genes. The RGS2 gene maps to chromosome 1q31, the locus for one form of monogenic hypertension, pseudohypoaldosteronism II (Mansfield et al. 1997). Yang et al. (2003) identified five missense variations in the RGS2 gene in a Japanese population. All of them, however, occurred as rare mutations (<1% allele frequency) only in their hypertensive cohort. Functional studies are presently missing; however, sequence analyses revealed that one mutation affects the core RGS motif, while the others change phylogenetically highly conserved amino acids, predominantly confined to the adenylyl cyclase interacting N-terminus and to a helix implicated in plasma membrane localization. In addition to these rare mutations, they identified two common RGS2 polymorphisms (T1026A located in intron 1, and 1891-1892del TC, located in intron 2) which were associated with hypertension. These associations, however, were only significant in women, the biological plausibility of which remains to be studied (Yang et al. 2003). Riddle and colleagues (2006) followed a similar approach in white and black Americans, and identified 16 variants in the RGS2 gene. Three variants affected the coding region but occurred at or below 1%. They also identified the 1891-1892TC insertion/deletion polymorphism, which was in complete linkage disequilibrium with the 2138-2139AA insertion/deletion polymorphism. While the 1891-1892TC deletion allele was significantly increased in black hypertensives (here without gender effect), there was no effect in whites (Riddle et al. 2006).
Genetic variants of G protein-coupled kinase 4
In addition to RGS proteins, G protein-coupled kinases (GRKs) are another system for the fine-tuning of GPCR-mediated signals. Phosphorylation of GPCRs by GRKs is an initial step in desensitization following receptor occupation with agonists. Next, the receptor binds to arrestins and other adaptor proteins, which leads to an uncoupling of the activated receptor from G protein complexes and terminates its function. Although different receptor classes vary, phosphorylated arrestin-complexed receptors undergo internalization via clathrin-coated pits, and cycle to an endosome where the receptor is dephosphorylated and recycled to the membrane or in other cases degraded in the lysosome or proteasome. There are several GRKs, including GRK1 and GRK7 that belong to the rhodopsin kinase family, GRK2 and GRK3 creating the β-adrenergic receptor kinase family, and GRK 4, 5 and 6 that belong to the GRK4 family. GRK2 is not only a receptor kinase but also contains an RGS domain, thus integrating two functions in attenuating GPCR signalling.
Dopamine has long been recognized as an important modulator of blood pressure, sodium balance and renal function. Within the kidneys, locally generated dopamine acts on renal tubular cells (in part from the tubular lumen) to decrease sodium transport under conditions of sodium excess (Fig. 14). While all dopamine receptor isoforms have been identified in the kidney, the D1 isoform appears to be the most important for the regulation of sodium balance, and the D1 receptor agonist fenoldopam is suitable for treatment of hypertensive emergencies. From human and animal studies, there is evidence for a renal dopamine receptor—or better signalling defect—in hypertension. Studies in the D1 receptor protein, G proteins, adenylyl cyclases, phospholipase C, sodium transporters or the sodium pump revealed no causal abnormalities, so far (for review of the renal dopaminergic system in hypertension see Zeng et al. 2004). Since the hypertensive phenotype with respect to renal dopamine signalling resembles processes observed in uncontrolled receptor desensitization, Felder et al. (2002) studied D1 receptor desensitization processes and observed an enhanced phosphorylation of the receptor protein at serine residues, which was attributed to an enhanced activity of the G protein-coupled receptor kinase 4 (GRK4). Four different splice variants of GRK4 are known, termed α, β, γ and δ. In contrast to other GRKs, GRK4 exhibits a restricted pattern of expression that includes brain, testes and the renal proximal tubule (Felder et al. 2002). Basal and stimulated GRK4 activity was enhanced in renal tubulus from hypertensive individuals, causing an increased desensitization of D1 receptor signalling. The GRK4 locus on chromosome 4p16 has been linked to hypertension (Allayee et al. 2001) and several amino acid exchanges in GRK4 were identified, including Arg65Leu, Ala142Val and Ala486Val (Felder et al. 2002). In vitro experiments revealed that the 65Leu, the 142Val and the 486Val variant appeared to be constitutively active and caused an increased phosphorylation of the D1 receptor, explaining the phenotype observed in some individuals with human hypertension (Fig. 14). Transgenic mice, overexpressing the GRK4γ isoform with the 142Val variant, exhibited increases in mean blood pressure by ∼30 mmHg compared to mice overexpressing the human wildtype variant (Felder et al. 2002). Mice overexpressing the GRK4 486Val variant were initally normotensive but developed hypertension on a sodium diet (Zeng et al. 2004).
In human hypertension, the common 486Val variant has been reported to be associated with salt-sensitive hypertension in Italians (Bengra et al. 2002). These results were confirmed in white Australians for the 486Val polymorphism, and were extended to several haplotypes that included the Arg65Leu and the Ala142Val variants (Speirs et al. 2004). Results published in abstract form indicate that GRK4 variants also affect the risk for hypertension in black African and Japanese populations (Zeng et al. 2004).
Polymorphisms in rho kinase gene (ROCK2)
Hypertension and stroke
Randomized controlled studies of pharmacological intervention in hypertension have unequivocally documented that blood pressure reduction lowers morbidity and mortality, with dramatic reductions in stroke mortality and smaller reductions in myocardial infarction. Despite this overwhelming evidence, stroke prevention has remained an area where academic medicine, with its evidence-based guidelines, and daily routine practice appear to belong to different worlds. Target blood pressure values are seldom reached, in part related to behaviours of physicians and patients. Current epidemiological data indicate that only ∼50% of individuals with hypertension are diagnosed. Of these, 41% receive an antihypertensive treatment that results in 60% and 30% response rates at thresholds of 160/95 and 140/90 mmHg respectively. This leads to the most unfavourable situation that only 8% of all hypertensive individuals are controlled at guideline levels of <140/90 mmHg (Wolf-Maier et al. 2004). Under these conditions, genetic abnormalities that markedly impact blood pressure variation should also materialize as stroke genes. For monogenic forms of hypertension, several reports of increased stroke frequency exist, including hypertension with brachydacytly (Bilginturan et al. 1973), glucocorticoid remediable hypertension (Rich et al. 1992; Litchfield et al. 1998), apparent mineralocorticoid excess (New et al. 1977), and Gordon’s syndrome (PHA2).
It is noteworthy that for genes implicated to essential hypertension, most studies failed so far to demonstrate an effect on stroke risk. On one hand, this may indicate that the contributions of each of those genes to blood pressure variation are so small that effects on stroke frequency remain undetectable, particularly if only hypertensive populations and not stroke samples are analysed. On the other hand, this also questions the relevance of such genes for clinical medicine. However, some exceptions exist.
Two studies investigated the contribution of adducin polymorphisms to the genetics of stroke. While one report failed to demonstrate an association between the Add1 460W allele and ischemic stroke (Morrison et al. 2001), Psaty and co-workers reported an increased risk for combined hemorrhagic and ischemic stroke in carriers of the Add1 460W allele, although there was no association to hypertension itself (Psaty et al. 2002). In the same study mentioned just above, Morrison and coworkers (2001) documented an increased frequency for subclinical strokes in carriers of the GNB3 T allele, again independent of an effect on blood pressure. Several groups have addressed the effect of the common ACE polymorphism on stroke. Two meta-analyses that reported significant positive associations between the ACE D allele and ischemic stroke (Maeda et al. 1996; Sharma 1998) prompted a prospective matched case-control study within the Physicians’ Health Study. Here, non-significant odds ratios for carriers of the D allele for ischemic stroke, ranging from 1.10–1.22, were observed (Zee et al. 1999). No association was shown between the AT1R polymorphism and stroke (Tiret et al. 1998; Sierra et al. 2002).
The key rationale for all efforts in unravelling the genetic basis of hypertension etiology is the search for novel antihypertensive drug targets and the prospect for a tailored individualized drug therapy. A given antihypertensive shows effective blood pressure reduction (>10 mmHg) in 50–60% of the patients. Hence, most hypertensive patients require two or more antihypertensive medications to reach target blood pressures, and the optimization of drug therapy for the individual patient is frequently driven by ‘trial and error’. Genetic mechanisms are supposed to contribute to these inter-individual variations addressed by the field of pharmacogenetics, which can further be divided into a pharmacokinetic part that analyzes genetic variations in drug metabolism and transport with respect to ultimate drug effects, and a pharmacodynamic part that addresses variations in drug targets. It deserves mention that key concepts in pharmagenetics have been derived from antihypertensive drugs. CYP2D6 polymorphisms were identified for their dramatic effects on debrisoquine plasma levels, an antihypertensive no longer in use for these reasons (Eichelbaum and Gross 1990). Frequently used β-blockers including metoprolol, however, are also subject to CYP2D6 metabolism, which explains inter-individual differences in their efficacies and adverse effects (Fux et al. 2005).
Pharmacogenetic aspects of antihypertensive therapy have been covered by several excellent recent reviews (Mellen and Herrington 2005; Koopmans et al. 2003; Turner and Boerwinkle 2003; Turner et al. 2001a,b). Therefore, we will summarize relevant results only pertaining to genes discussed above, which completely neglects the whole field of drug disposition.
Since adducin polymorphisms are supposed to affect renal sodium handling, some groups have addressed potential implications for diuretic therapy, and confirmed a greater blood pressure response to hydrochlorothiazide in carriers of the 460W allele (Cusi et al. 1997; Glorioso et al. 1999, 2002), in part as an interaction with ACE gene polymorphisms (Sciarrone et al. 2003). In a large study with 595 hypertensive white and African Americans, however, no effect of the Add1 460W allele on blood pressure responses to hydrochlorothiazide was observed (Turner et al. 2003). As mentioned above, Psaty et al. (2002) followed a managed-care group of 1038 hypertensive individuals for several years. They observed that treatment with diuretics led to a relative reduction in incidences for stroke and myocardial infarction of almost 50% in carriers of the Add1 460W allele compared to other antihypertensive agents that produced a similar blood pressure reduction. A straightforward interpretation of these results indicates that the α-adducin system affects blood pressure-independent mechanisms in stroke pathogenesis that remain to be elucidated. The same group documented that therapy with ACE inhibitors resulted in differential protection from non-fatal stroke, depending on the AGT M235T genotype status (Bis et al. 2003).
Common polymorphisms in components of the RAS system have also been investigated for potential effects on antihypertensive treatments. One report showed that homozygous carriers of the I allele of the common ACE I/D polymorphism exhibited larger reductions in systolic blood pressure after 2 weeks treatment with hydrochlorothiazide (Sciarrone et al. 2003). Another group, however, were able to confirm the effect of the I allele on thiazide effects only for women, while they observed opposite reponses in males, a result that underscores the complexities of genetic interaction, if confirmed (Schwartz et al. 2002). For homozygous carriers of the wild-type AGT 235M allele or of the AGT promoter polymorphism -6G allele atenolol responses on systolic blood pressure were blunted (Kurland et al. 2004), a finding that may relate to antihypertensive mechanisms of β-blockers via inhibition of renin release. Another group observed a similar trend for blood pressure responses, which did, however, not reach statistical significance (Dudley et al. 1996). Several trials have been conducted for effects of the ACE I/D polymorphism on blood pressure responses to ACE inhibitors, documenting contradictory results, with greater responses in homozygous carriers of the D allele (Mondorf et al. 1998; Ueda et al. 1998; Stavroulakis et al. 2000), no difference (Hingorani et al. 1995; Dudley et al. 1996; Sasaki et al. 1996; Nakano et al. 1997; Harrap et al. 2003) and greater responses in homozygous carriers of the I allele (Ohmichi et al. 1997). For treatment with angiotensin receptor blockers, again one group reported that homozygous carriers of the I allele exhibited increased responses (Kurland et al. 2001). Similarly, for the AGT M235T polymorphism, one trial with ACE inhibitors provided evidence for an association of homozygous carriers of the M allele with ‘poor responder’ status (Hingorani et al. 1995), while two other groups refuted this finding (Dudley et al. 1996; Mondorf et al. 1998).
Since β-blockers modulate the actions of the β1 adrenoceptor, obvious candidates for pharmacogenetic effects are components of the G protein-coupled receptor system. While some groups reported enhanced β-blocker responses in homozygous carriers of the gain-of-function 389R allele in small studies (metoprolol: Liu et al. 2003; Johnson et al. 2003; atenolol: Sofowora et al. 2003), others did not observe effects of the G389R and the S49G polymorphisms in the β1 adrenoceptor gene on β-blocker responses (Filigheddu et al. 2004; Karlsson et al. 2004; O’Shaughnessy et al. 2000). A recent study reported 9% decreases in mean blood pressures for homozygous hypertensives with the 49S389R haplotypes, while blood pressure decreases were virtually absent in homozygous carriers of the 49S389G haplotypes or in 49S389G/49G389G diplotypes (Liu et al. 2006). Mixed results were also obtained for the T393C polymorphism in the GαS gene, the next step in signal transduction of the β1 adrenoceptor. While Jia et al. (1999) documented that the T-allele that was associated with enhanced blood pressure, predicted a poor response to β-blocker, others refuted this association (Filigheddu et al. 2004). Blood pressure-lowering responses of Atenolol in 221 hypertensive individuals were significantly enhanced in homozygote carriers of the GNB3 C allele. One interpretation is that under conditions of increased signalling (in case of the GNB3 T-allele) higher doses of a β-blocker could be necessary to achieve a comparable blood pressure response (Filigheddu et al. 2004). On the other hand, Turner et al. documented significantly greater decreases in systolic and diastolic blood pressure after a 4-week treatment period with hydrochlorothiazide for carriers of the GNB3 T-allele (Turner et al. 2001a,b), an astonishing result, since heterotrimeric G proteins do not contribute to early effects of diuretics. Full antihypertensive effects of diuretics, however, require latencies of several weeks, indicating complex adaptation processes in vascular reactivity for which an involvement of G protein-coupled mechanisms is highly probable. In a follow-up survey, this group, however, was not able to reproduce this observation (Turner et al. 2003). Such adaptation processes could also explain the effect of a common polymorphism in the gene for endothelial nitric oxide synthase on hydrochlorothiazide-induced responses in hypertensives. In this report, the effect of this polymorphism contributed to only 1% to the observed inter-individual variation after adjusting for age, gender, race, and waist-to-hip ratio, a ‘magnitude’ of effect that was similar with other polymorphisms, at best (Turner et al. 2003).
Conclusions and future developments
Considerable financial funding, vast human resources and immeasurable individual efforts have been spent to unravel the enigma ‘genetics of hypertension’. The promises of the clarification of the etiology of primary hypertension are suitable preclinical diagnosis procedures, the delineation of hypertensive pathways, the discovery of novel drug targets which will ultimately result in tailored individualized therapeutic regimes. Actually, lessons from monogenetic forms of hypertension have considerably expanded our molecular, cellular and systemic understanding of salt und volume regulation, of mineralocorticoid action and of the signalling involved in regulation of ion transporter and channel activity. Given the diversity of physiologic systems that affect blood pressure, it is perhaps surprising that almost all gene products in monogenic hypertension affect salt absorption in the kidneys. While monogenic diseases impart large effects to small numbers of patients, we are still at the beginning of addressing the small effects of polygenic ‘complex’ mechanisms on large numbers of patients. At best, analyses of common variants linked to essential hypertension explain only a small fraction of the observed variance in blood pressure in the general population. Lack of consistent reproduction appears to be the destiny of many common polymorphisms implicated in the genesis of complex diseases, which underscores the difficulties of genetic research into multifactorial traits. While we have evidence for modest effects of some polymorphisms on a statistical level, for individuals we are far from predicting the genetic risk for hypertension with sufficient precision (if at all) to allow us to improve diagnosis, prevention or differential therapy. Upon demonstration of an initial association, subsequent studies fail to confirm or may refute earlier findings (Anonymous 1999; Hirschhorn et al. 2002). Low sample sizes, limited statistical power, low genotype-relative risks, heterogeneity of studied populations and genetic admixture, publication bias, imperfect characterization of patients and controls, context dependency and epistasis may contribute to these sobering results. Hence, adequate sample sizes, adequate recognition of the ethnic identity of the enrolled subjects, use of family studies if possible, preference of haplotype-based analyses over single SNPs, and the careful consideration of biological plausibilities from the molecular to the systemic level are urgently needed.
With regard to pharmacogenetics, the available basis of evidence cannot be taken as sound. Currently, patient numbers in trials has never exceeded 200 per ethnicity at best, and most trials have addressed several polymorphisms in parallel, generating considerable statistical problems. For instance, the SILVHIA study—which is the largest trial addressing pharmacogenetic effects of angiotensin receptor blockade or atenolol treatment in hypertension—analyzed 74 SNPs in each 100 patients, providing ample opportunity for spurious associations (Kurland et al. 2004). It will be important for future pharmacogenetic studies that independent researchers get access to industry-sponsored trials, and that the consideration of pharmacogenetic issues is mandatory for regulatory measures. To nurture the growth of pharmacogenetics from basic science to clinical medicine, outcome-oriented research representative of clinical reality is required to provide a useable basis for a genetic assessment of risks and benefits.
Current approaches try to unravel the genetic mysteries of essential hypertension in genome-wide linkage analyses, in part analyzing huge and well-characterized human samples, e.g. from the Framingham Heart Study, the MRC-funded British Genetics of Hypertension (BRIGHT; 1599 families with 2010 sibling pairs) study, and the NIH-funded Family Blood Pressure Program (FBPP). Again, the results published so far are disappointing, with either no linkage or comparably weak linkages, e.g. to chromosomes 1, 2, 5, 6, 9 or 17, which do not overlap between different trials (Hsueh et al. 2000; Levy et al. 2000; Thiel et al. 2003; Caulfield et al. 2003; Wallace et al. 2006). Candidate gene approaches revealed a wealth of interesting and not so interesting associations, but also failed to uncover relevant hypertension candidate genes so far. The future will show whether hypertension research will succeed in the identification of a manageable number of hypertension candidate genes that will be useful for clinical medicine. Otherwise, it is also possible that we will face a situation with a large number of genes and a myriad of polymorphism that may actually affect blood pressure values in individuals, in ways, however, not suitable for prediction in daily routine. In the meantime, we have already learned and we will learn how—at first glance—completely different systems of ion transport, membrane trafficking, and signal transduction interplay to control salt and volume homeostasis and vasoconstriction. Hypertension research has sparked fascinating work into novel protein families including WNK kinases, special RGS proteins or GRKs. Whether this research will ultimately unravel hypertension genetics remains open. However, we should be optimistic that these efforts open the way for a better understanding of the complex renal and vascular regulation, and in the end may provide us with novel drug targets and potentially innovative classes of antihypertensive therapeutics.